Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Paul R. Kalra(Salford Royal NHS Foundation Trust), Claes Christian Strom, Mark C. Petrie(British Heart Foundation), Shannon Amoils, Richard Mindham(European Society of Cardiology), Ian Ford, John G.F. Cleland(University of Glasgow), Iain C. Macdougall(King's College Hospital), Michele Robertson(University of Glasgow), Alan G. Japp(Edinburgh Royal Infirmary), Rebecca Lane(Harefield Hospital), Pierpaolo Pellicori(University of Glasgow), Peter J. Cowburn(University Hospital Southampton NHS Foundation Trust), Alison Seed(Blackpool Teaching Hospitals NHS Foundation Trust), Fraser J Graham(University of Glasgow), Abdallah Al‐Mohammad(Unknown), Paul W X Foley(Great Western Hospital), Elizabeth Thomson(University of Glasgow), Iain Squire(University of Leicester), Fozia Ahmed(Keele University), Andrew Ludman(Royal Devon & Exeter NHS Foundation Trust), Pamela Sandu, Philip A. Kalra(University of Manchester), Robin Ray(St George’s University Hospitals NHS Foundation Trust), Nicholas A. Boon, Thomas G Diness, Callum Chapman, Ninian N. Lang(British Heart Foundation)
Cited by 367
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Journal of Heart Failure|2022|2.1k